抗生素浸渍补片预防包膜挛缩复发:单术者经验
该回顾性病例系列纳入18例(31侧乳房)Baker III或IV级包膜挛缩患者,行包膜切除、假体更换及抗生素可吸收补片置于假体前方。术后平均随访54.7个月,5侧乳房(16.1%)复发包膜挛缩,1例血肿需再手术。结论提示该补片安全性良好,可能减少包膜挛缩复发,但需进一步研究验证。
要点
- 包膜切除联合抗生素可吸收补片置入假体前方,术后包膜挛缩复发率为16.1%。
- 术后即刻并发症包括1例血肿,经再手术处理。
- 该技术安全性良好,但需进一步研究验证其疗效。
核心结论
- 抗生素浸渍补片安全性良好,可能减少包膜挛缩复发。
- 需进一步研究评估结局并验证该技术。
研究设计与样本
- 回顾性病例系列,单术者经验。
- 纳入18例(31侧乳房)包膜挛缩患者,随访不足24个月者排除。
- 所有患者行包膜切除、假体更换及抗生素可吸收补片置于假体前方。
主要发现
- 包膜挛缩出现时平均年龄50.9±9.0岁,距原假体置入平均166.1个月。
- 术后平均随访54.7个月,5侧乳房(16.1%)复发包膜挛缩。
- 术后即刻并发症为1例血肿,经再手术处理。
- 所有患者就诊时均为Baker III或IV级包膜挛缩。
临床怎么用
- 对Baker III或IV级包膜挛缩患者,可考虑包膜切除、假体更换联合抗生素可吸收补片置入。
- 术后需关注血肿等即刻并发症,必要时再手术。
局限性
- 回顾性病例系列,样本量小(18例31侧乳房),单术者经验。
- 描述性分析,无对照组,无法确定补片相对于其他处理的疗效。
- 随访不足24个月者被排除,可能影响复发率评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Capsular contracture remains the leading cause of revision surgery following implant-based breast augmentation, with growing evidence suggesting that biofilm may play a key role in its formation. This study aimed to evaluate the effectiveness of using an antibacterial envelope in reducing the recurrence of capsular contracture. METHODS: This retrospective case series included patients presented with capsular contracture. All patients underwent capsulectomy with implant replacement and placement of an antibiotic absorbable mesh placed anterior to the implant. Demographic information, implant data, and postoperative outcomes were collected. Patients with less than 24 months of follow-up were excluded from the study. Descriptive analysis was performed using Microsoft Excel. RESULTS: A total of 18 patients (31 breasts) were included in this study. The mean age at the presentation of capsular contracture was 50.9 ± 9.0 years, and the mean duration since the placement of the original implant was 166.1 months. Mean postoperative follow-up was 54.7 months. All patients had Baker grade III or IV capsular contracture at presentation. Following capsulectomy with mesh placement, recurrence of capsular contracture occurred in five breasts (16.1%). Immediate postoperative complications included one hematoma that was treated with reoperation. CONCLUSIONS: Our findings highlight the safe profile and potential use of antibiotic-impregnated mesh in reducing the capsular contracture recurrence. Further investigation is warranted to assess the outcomes and validate this technique for managing capsular contracture.
引用
- Miao XC, Ruff ES, Rude MJ, et al. The role of antibiotics-impregnated mesh in preventing capsular contracture recurrence: A single-surgeon experience. J Plast Reconstr Aesthet Surg. 2025. PMID: 41043340. doi:10.1016/j.bjps.2025.09.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。